Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer networkDo the results of international clinical trials translate into a similar benefit for patients in South East Wales

British Journal of Cancer

Volumn 106, Issue 1, 2012, Pages 32-38

  Webster, R M ^a   Abraham, J ^a   Palaniappan, N ^a   Caley, A ^a   Jasani, B ^b   Barrett Lee, P ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

adjuvant; HER2+; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SURGERY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DATA BASE; DIAGNOSTIC TEST; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; TREND STUDY; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; GREAT BRITAIN; HUMANS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; WALES;

EID: 84855342713     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.506     Document Type: Article

References (20)

1. Banerjee S, Smith IE (2010) Management of small HER2-positive breast cancers. Lancet Oncol 11(12): 1193-1199
2. Coulson SG, Kumar VS, Manifold IM, Hatton MQ, Ramakrishnan S, Dunn KS, Purohit OP, Bridgewater C, Coleman RE (2010) Review of testing and use of adjuvant trastuzumab across a cancer network-are we treating the right patients? Clin Oncol 22(4): 289-293
3. CRUK (2011) Cancer incidence for common cancers-UK statistics. http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/. Accessed August 2011
4. Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nole F, Goldhirsch A (2009) Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27(34): 5693-5699
5. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12(3): 236-244
6. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1cm or smaller. J Clin Oncol 27(34): 5700-5706
7. Joerger M, Thurlimann B, Huober J (2011) Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? Ann Oncol 22(1): 17-23
8. Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L (2011) Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol 22(11): 2387-2393
9. Murray LJ, Ramakrishnan S, O0Toole L, Manifold IH, Purohit OP, Coleman RE (2010) Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. Breast 19(5): 339-344
10. NICE (2006) TA107 Breast Cancer (Early)-Trastuzumab: Guidance. National Institute for Health and Clinical Excellence: London
11. Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios C, Steger G, Huang C, Andersson M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter T, Rüschoff J, Süto T (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16): 1659-1672 (Pubitemid 41464705)
12. Rodrigues MJ, Wassermann J, Albiges L, Brain E, Delaloge S, Stevens D, Guinebretiere JM, Mathieu MC, Kirova Y, Guillot E, Vincent-Salomon A, Cottu PH (2010) Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. J Clin Oncol 28(28): e541-e542
13. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16): 1673-1684 (Pubitemid 41464706)
14. Schmidt F, Hartwagner KA, Spork EB, Groell R (1998) Medical audit after 26,711 breast imaging studies: improved rate of detection of small breast carcinomas (classified as Tis or T1a,b). Cancer 83(12): 2516-2520 (Pubitemid 29019571)
15. Slamon D, Eiermann W, Robert N (2006) BCIRG 006: Second interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclo-phosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients. In: Annual San Antonio Breast Cancer Symposium 100 pp S1-299 (abstract 52). San Breast Cancer Res Treat: Antonio, Texas, USA
16. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785): 177-182 (Pubitemid 17231334)
17. Sobin L, Gospodarowicz M, Wittekind C (2009) International Union Against Cancer (UICC) TNM Classification of Malignant Tumors, 7th edn. Wiley-Blackwell: Oxford, UK
18. Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J (2009) Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 100(5): 680-683
19. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7: 153
20. Webster R, Palaniappan N, Abraham J, Bertelli G, Jasani B, Barrett-Lee P (2010) HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales. Clin Oncol 22(10): 894-894